Xbrane Biopharma

Share Issue/Capital Change • Nov 30, 2020

Change of number of shares and votes in Xbrane

Xbrane Biopharma AB ("Xbrane" or the "Company") has according to previously announced information resolved to carry out a directed share issue of in total 2,919,708 shares. The share issue has resulted in a change of the registered share capital and shares and votes in Xbrane.

As of November 30, 2020 the total number of shares and votes in the Company amounts to 22,200,415. The Company's registered share capital amounts to approximately SEK 4,977,023.

Contacts

Martin Åmark, CEO/ IR M: +46 (0) 763-093 777 E: martin.amark@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally four biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.

This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2020-11-30 08:00 CET.

Attachments

Change of number of shares and votes in Xbrane